Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Debt (2020 - 2024)

Bicycle Therapeutics' Non-Current Debt history spans 5 years, with the latest figure at $8.5 million for Q2 2024.

  • For Q2 2024, Non-Current Debt fell 72.13% year-over-year to $8.5 million; the TTM value through Jun 2024 reached $8.5 million, down 72.13%, while the annual FY2023 figure was $30.7 million, 1.26% up from the prior year.
  • Non-Current Debt reached $8.5 million in Q2 2024 per BCYC's latest filing, down from $30.8 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $30.8 million in Q1 2024 to a low of $8.5 million in Q2 2024.
  • Average Non-Current Debt over 5 years is $26.9 million, with a median of $30.1 million recorded in 2022.
  • Peak YoY movement for Non-Current Debt: skyrocketed 106.23% in 2021, then plummeted 72.13% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $14.5 million in 2020, then soared by 105.95% to $29.9 million in 2021, then increased by 1.48% to $30.3 million in 2022, then rose by 1.26% to $30.7 million in 2023, then plummeted by 72.29% to $8.5 million in 2024.
  • Per Business Quant, the three most recent readings for BCYC's Non-Current Debt are $8.5 million (Q2 2024), $30.8 million (Q1 2024), and $30.7 million (Q4 2023).